AstraZeneca (LON:AZN) Stock Rating Reaffirmed by Shore Capital

Share on StockTwits

Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a research report report published on Friday, ThisIsMoney.Co.Uk reports.

A number of other equities research analysts have also recently issued reports on the company. Jefferies Financial Group reiterated a buy rating and issued a C$15.00 target price on shares of Aphria in a research note on Friday, May 24th. Credit Suisse Group reiterated a sell rating and issued a $6.50 target price on shares of Deutsche Bank in a research note on Monday, April 29th. Goldman Sachs Group cut EXPERIAN PLC/ADR from a buy rating to a neutral rating in a research note on Wednesday, July 10th. UBS Group upgraded to a neutral rating and raised their target price for the company from GBX 945 ($12.35) to GBX 2,060 ($26.92) in a research note on Thursday, June 20th. Finally, Morgan Stanley raised their target price on SYSCO from $69.00 to $72.00 and gave the company an equal weight rating in a research note on Tuesday, May 7th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of Hold and an average target price of GBX 6,502.94 ($84.97).

AZN stock opened at GBX 6,331 ($82.73) on Friday. The company has a debt-to-equity ratio of 179.66, a current ratio of 0.75 and a quick ratio of 0.57. The company has a market capitalization of $83.05 billion and a PE ratio of 33.32. AstraZeneca has a 1 year low of GBX 5,312 ($69.41) and a 1 year high of GBX 6,634 ($86.68). The company has a fifty day moving average of GBX 6,262.20.

In related news, insider Philip A. J. Broadley acquired 520 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The shares were acquired at an average cost of GBX 5,738 ($74.98) per share, for a total transaction of £29,837.60 ($38,988.11). Also, insider Marc Dunoyer acquired 8,500 shares of the business’s stock in a transaction that occurred on Tuesday, May 7th. The shares were bought at an average price of GBX 5,800 ($75.79) per share, for a total transaction of £493,000 ($644,191.82).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: What are the advantages to having securities held in street name?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Cognizant Technology Solutions Corp  Stake Cut by Reynders McVeigh Capital Management LLC
Cognizant Technology Solutions Corp Stake Cut by Reynders McVeigh Capital Management LLC
Reynders McVeigh Capital Management LLC Reduces Stock Position in Air Products & Chemicals, Inc.
Reynders McVeigh Capital Management LLC Reduces Stock Position in Air Products & Chemicals, Inc.
Elite Reaches Market Cap of $418,029.00
Elite Reaches Market Cap of $418,029.00
EveryCoin  Reaches Market Cap of $2.63 Million
EveryCoin Reaches Market Cap of $2.63 Million
Matryx  Reaches 24-Hour Trading Volume of $337,697.00
Matryx Reaches 24-Hour Trading Volume of $337,697.00
W Green Pay  Price Tops $0.20 on Major Exchanges
W Green Pay Price Tops $0.20 on Major Exchanges


 
© 2006-2019 Zolmax.